Peter Thompson Sells 52,397 Shares of Sionna Therapeutics (NASDAQ:SION) Stock

Sionna Therapeutics, Inc. (NASDAQ:SION) Director Peter Thompson sold 52,397 shares of the firm’s stock in a transaction on Friday, April 17th. The shares were sold at an average price of $44.68, for a total value of $2,341,097.96. Following the completion of the sale, the director directly owned 2,967,722 shares of the company’s stock, valued at approximately $132,597,818.96. This trade represents a 1.73% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Sionna Therapeutics Stock Performance

Sionna Therapeutics stock opened at $43.20 on Thursday. Sionna Therapeutics, Inc. has a one year low of $10.97 and a one year high of $46.46. The business has a fifty day moving average of $38.07 and a two-hundred day moving average of $38.66. The company has a market cap of $1.94 billion, a P/E ratio of -22.15 and a beta of 3.01.

Sionna Therapeutics (NASDAQ:SION) last released its earnings results on Monday, March 2nd. The company reported ($0.46) EPS for the quarter, beating analysts’ consensus estimates of ($0.61) by $0.15. Sell-side analysts predict that Sionna Therapeutics, Inc. will post -2.44 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on SION shares. Guggenheim raised their target price on Sionna Therapeutics from $45.00 to $50.00 and gave the company a “buy” rating in a report on Monday, March 2nd. Raymond James Financial restated a “strong-buy” rating and issued a $53.00 price target on shares of Sionna Therapeutics in a research report on Monday, January 5th. UBS Group restated a “buy” rating on shares of Sionna Therapeutics in a research report on Monday, March 2nd. Citizens Jmp began coverage on Sionna Therapeutics in a research report on Tuesday, February 24th. They issued a “market outperform” rating and a $63.00 price target for the company. Finally, Lifesci Capital upgraded Sionna Therapeutics to a “strong-buy” rating in a research report on Wednesday, February 25th. Two research analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat, Sionna Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $50.57.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the company. GF Fund Management CO. LTD. purchased a new stake in Sionna Therapeutics during the 4th quarter worth about $36,000. Russell Investments Group Ltd. purchased a new stake in Sionna Therapeutics during the 3rd quarter worth about $30,000. Balyasny Asset Management L.P. purchased a new stake in Sionna Therapeutics during the 4th quarter worth about $58,000. BNP Paribas Financial Markets purchased a new stake in Sionna Therapeutics during the 2nd quarter worth about $31,000. Finally, Mirae Asset Global Investments Co. Ltd. purchased a new stake in Sionna Therapeutics during the 4th quarter worth about $89,000.

About Sionna Therapeutics

Sionna Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation RNA therapeutics for oncology and immunology indications. Leveraging proprietary lipid nanoparticle and coacervate delivery technologies, the company aims to overcome key challenges associated with stability, targeting and immune activation that have historically limited the clinical performance of mRNA-based medicines. Its strategic focus spans both solid tumors and hematological malignancies, as well as selected autoimmune disorders, reflecting a broad ambition to harness the power of messenger RNA in diverse therapeutic areas.

At the heart of Sionna’s approach is a platform that combines optimized ionizable lipids with bespoke surface chemistries to enhance payload delivery, intracellular release and endosomal escape.